These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 10192107)

  • 1. Inclusion complexation of furosemide in cyclodextrins. Part 2: Implication on bioavailability.
    Ammar HO; Ghorab M; Emara LH; el-Nahhas SA; Makram TS
    Pharmazie; 1999 Mar; 54(3):207-10. PubMed ID: 10192107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters.
    Wolf-Coporda A; Lovrić Z; Huić M; Francetić I; Vrhovac B; Plavsić F; Skreblin M
    Int J Clin Pharmacol Res; 1996; 16(4-5):83-8. PubMed ID: 9172005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers.
    Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
    Biopharm Drug Dispos; 2003 Sep; 24(6):245-9. PubMed ID: 12973821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable furosemide absorption and poor predictability of response in elderly patients.
    Murray MD; Haag KM; Black PK; Hall SD; Brater DC
    Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and pharmacokinetics of furosemide marketed in Thailand.
    Kaojarern S; Poobrasert O; Utiswannakul A; Kositchaiwat U
    J Med Assoc Thai; 1990 Apr; 73(4):191-7. PubMed ID: 2394955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability study of furosemide prodrugs in rats.
    Prandi C; Fagiolino P; Manta E; Dominguez Llera L
    Farmaco; 1992 Sep; 47(9):1225-34. PubMed ID: 1300128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
    Lesne M
    Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit.
    Pichette V; Geadah D; du Souich P
    Drug Metab Dispos; 1999 Jan; 27(1):81-5. PubMed ID: 9884313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of oral bioavailability of fenbufen by cyclodextrin complexations.
    Miyaji T; Inoue Y; Acartürk F; Imai T; Otagiri M; Uekama K
    Acta Pharm Nord; 1992; 4(1):17-22. PubMed ID: 1515048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Features of the pharmacodynamics and pharmacokinetics of furosemide upon long-term administration in rats].
    Briukhanov VM; Zverev IaF; Lampatov VV; Zharikov AIu
    Eksp Klin Farmakol; 2007; 70(2):33-6. PubMed ID: 17523448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects.
    Abou-Auda HS
    Int J Clin Pharmacol Ther; 1998 May; 36(5):275-81. PubMed ID: 9629992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancy among dissolution rates of commercial tables as a function of the dissolution method. Part 7: Aspirin.
    Ammar HA; el-Nahhas SA; Emara LH; Ghorab MM; Salama HA
    Pharmazie; 1997 Feb; 52(2):145-9. PubMed ID: 9122273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aqueous solubilization of furosemide by supramolecular complexation with 4-sulphonic calix[n]arenes.
    Yang W; de Villiers MM
    J Pharm Pharmacol; 2004 Jun; 56(6):703-8. PubMed ID: 15231034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of SBA-15 for furosemide oral delivery enhancement.
    Ambrogi V; Perioli L; Pagano C; Marmottini F; Ricci M; Sagnella A; Rossi C
    Eur J Pharm Sci; 2012 May; 46(1-2):43-8. PubMed ID: 22365882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
    Arima H; Yunomae K; Hirayama F; Uekama K
    J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NXY-059 does not significantly interact with furosemide in healthy volunteers.
    Strid S; Nilsson D; Borgå O; Wemer J; Grahnén A
    J Clin Pharmacol; 2006 Dec; 46(12):1417-25. PubMed ID: 17101741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
    Klausner EA; Lavy E; Stepensky D; Cserepes E; Barta M; Friedman M; Hoffman A
    J Clin Pharmacol; 2003 Jul; 43(7):711-20. PubMed ID: 12856384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection, quantification, and pharmacokinetics of furosemide and its effects on urinary specific gravity following IV administration to horses.
    Dirikolu L; Lehner AF; Hughes C; Karpiesiuk W; Camargo FC; Harkins JD; Woods WE; Bosken JM; Boyles J; Troppmann A; Fisher M; Tobin T
    Vet Ther; 2003; 4(4):350-63. PubMed ID: 15136977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and bioavailability of cefquinome in healthy piglets.
    Li XB; Wu WX; Su D; Wang ZJ; Jiang HY; Shen JZ
    J Vet Pharmacol Ther; 2008 Dec; 31(6):523-7. PubMed ID: 19000274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative bioavailability of two cefadroxil products using serum and urine data in healthy human volunteers.
    Otoom S; Hasan M; Najib N
    Clin Exp Pharmacol Physiol; 2004 Jul; 31(7):433-7. PubMed ID: 15236630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.